Berlin, Germany

Andreas Gruetzkau

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Deutsches Rheuma-Forschungszentrum Berlin. Active years: 2018.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Andreas Gruetzkau: Innovator in Flow Cytometry

Introduction

Andreas Gruetzkau is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of flow cytometry through his innovative work. His expertise lies in the analysis of emission spectra, which is crucial for various scientific applications.

Latest Patents

Andreas Gruetzkau holds a patent for a system that utilizes principal component analysis (PCA) for the analysis of discontinuous emission spectra in multichromatic flow cytometry. This invention relates to a method for acquiring and analyzing discontinuous emission spectra data using a multivariate statistical model. The application of this system enhances the capabilities of flow cytometry, making it a valuable tool in research.

Career Highlights

Gruetzkau is affiliated with the Deutsches Rheuma-Forschungszentrum Berlin, where he applies his expertise in flow cytometry. His work has been instrumental in advancing the understanding of complex biological systems through innovative analytical techniques.

Collaborations

Some of his notable coworkers include Toralf Kaiser and Jenny Kirsch, who have collaborated with him on various projects. Their combined efforts contribute to the ongoing research and development in the field.

Conclusion

Andreas Gruetzkau's contributions to flow cytometry through his patent and collaborative work highlight his role as an innovator in the scientific community. His advancements in the analysis of emission spectra are paving the way for future research and applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…